Hyundai Bioscience Valuation

Q: What is the Fair Price of A048410 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A048410 (₩14490) is trading above our estimate of [[fair value]] (₩8617.03)

Is A048410 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A048410 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A048410 (₩14490) is trading above our estimate of fair value (₩8617.03)

Significantly Below Fair Value: A048410 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A048410?

Key metric: As A048410 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A048410. This is calculated by dividing A048410's market cap by their current revenue.
What is A048410's PS Ratio?
PS Ratio	36.5x
Sales	₩15.82b
Market Cap	₩576.98b

A048410 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	37.6x
Enterprise Value/EBITDA	790.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A048410's PS Ratio compare to its peers?

The above table shows the PS ratio for A048410 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.7x
A241710 Cosmecca Korea	1.1x	15.8%	₩562.8b
A237880 CLIO CosmeticsLtd	0.9x	11.9%	₩314.7b
A018290 VT	2.6x	n/a	₩1.1t
A439090 Manyo Factory	2.1x	22.6%	₩274.7b
A048410 Hyundai Bioscience	36.5x	n/a	₩577.0b

Price-To-Sales vs Peers: A048410 is expensive based on its Price-To-Sales Ratio (36.5x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does A048410's PS Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
A044820 Cosmax BTI	0.1x	n/a	US$59.38m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A048410 is expensive based on its Price-To-Sales Ratio (36.5x) compared to the KR Personal Products industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is A048410's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A048410 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	36.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A048410's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NOVAREXLtd

₩135.8b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,670.00

-0.1%

-29.5%

Cosmecca Korea

₩562.8b

Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.

A241710

₩52,700.00

-6.2%

47.2%

Cosmax

₩1.5t

Researches, develops, produces, and manufactures cosmetic and health function food products in Korea and internationally.

A192820

₩133,100.00

1.4%

16.9%